Rekombinanter RSV (Palivizumab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter RSV (Palivizumab Biosimilar) Antikörper (ABIN7795088)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Güteklasse
-
-
Expressionssystem
- Mammalian cells
-
Verwendungszweck
- Palivizumab Biosimilar, Endotoxin 0.05 EU/mg
-
Produktmerkmale
- Palivizumab, a humanized anti-RSV (respiratory syncytial virus) monoclonal antibody, targets an epitope in the A antigenic site of the F protein of RSV, inhibiting its entry into the cell and thereby preventing infection.
-
Aufreinigung
- Protein A or G affinity column
-
Reinheit
- >95 % by reducing SDS-PAGE
-
Endotoxin-Niveau
- Less than 0.5 EU/mg of protein as determined by LAL method
-
Immunogen
- Respiratory Syncytial Virus F protein
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- > 3 mg/mL
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- RSV (Palivizumab Biosimilar)
-
Andere Bezeichnung
- Palivizumab Biosimilar
-
Substanzklasse
- Biosimilar
Target
-